LIXTE Biotechnology Expands Collaboration With University Of Texas MD Anderson Cancer Center And GSK On Ongoing Clinical Trial With LIXTE's Proprietary Compound, LB-100, To Treat Ovarian Clear Cell Cancer

--Plans to double the Number of Patients in Study-- 

--Company Expects Initial Findings to be presented in 2026--

BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a biotech company focused on advancing cancer treatments, today announced it is expanding its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial with LIXTE's proprietary compound, LB-100, to treat ovarian clear cell cancer.

The trial, which combines LB-100 with GSK's Dostarlimab to enhance the effectiveness of immunotherapy, was initiated in January 2024. It is directed by lead clinical investigator Amir Jazaeri, MD, Professor of Gynecologic Oncology, at MD Anderson.

A second trial site was added earlier this year at the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University, led by Emily M. Hinchcliff, MD, MPH.

MD Anderson and Northwestern Medical Center plan to double the number of enrollments in the trial to 42 patients, after successfully attaining its initial target of 21 patients earlier this year. The Company also announced that it expects data to be presented from the trial on the initial 21 patients in the first half of 2026.